𝗘𝘅𝗲𝗰𝘂𝘁𝗶𝘃𝗲 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝘆 𝗠𝗲𝗲𝘁𝘀 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗥𝗲𝗮𝗹𝗶𝘁𝘆.

Innovation is expensive. Solvency is mandatory. Margins die in the gap between strategy and execution.

Medsolve Dynamics exists to close that gap. We work with oncology and MedTech organizations making capital decisions they can't reverse, managing reimbursement pressure they didn't budget for, and evaluating AI tools that don't map to their actual workflow.

𝗧𝗵𝗲 𝗥𝗲𝗮𝗹𝗶𝘁𝘆
Oncology delivery operates with minimal margin for error. In radiation oncology alone, expense ratios routinely approach 75 percent. Too often, the ROI promised in a capital or technology decision evaporates when it reaches the P&L. We validate whether you can staff it, schedule it, and pay for it before you sign.

𝗧𝗵𝗲 𝗙𝗶𝗿𝗺
Led by Yoel Bakas, who spent 20 years on the vendor side of every major deal in radiation oncology. GE HealthCare, ViewRay, Varian, Mevion. That experience now sits on your side of the table. Senior executive strategy and capital discipline are paired with ground-level validation from active clinical physicists and hospital administrators. Recommendations survive operational, regulatory, and accreditation reality.

𝗪𝗵𝗲𝗿𝗲 𝗪𝗲 𝗔𝗿𝗲 𝗧𝗿𝘂𝘀𝘁𝗲𝗱
Our work concentrates where execution risk is highest and failure is expensive.
Capital Strategy: Vendor-neutral deal structure, service contract intelligence, and negotiation leverage.

Financial Strategy: Revenue protection, workflow defense, and reimbursement exposure and APEx/ACR complexity.

AI Reality Check: Separating what works from what a vendor told you would work.

Revenue & Margin Growth: Theranostics, benign disease, adaptive therapy, and high-margin service line frameworks.

Our principle is simple.
You cannot buy the future of cancer care if you cannot pay for the present.

𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲
Main site: medsolvedynamics.com
2026 Executive Diagnostic: medsolve.ai

Medsolve Dynamics

Org chart

Teams

Offices